Topical Corticosteroid Treatment Guidelines

Introduction to Topical Corticosteroids

The American Academy of Dermatology recommends fluticasone propionate 0.05% cream for inflammatory skin conditions 1

Mid-potency corticosteroids are recommended for initial therapy in adults with plaque psoriasis not involving intertriginous areas, as suggested by the American Academy of Dermatology 2
High-potency corticosteroids are recommended for areas with thick, chronic plaques, according to the American Academy of Dermatology 2
For localized or mild disease, very potent topical steroids can be applied to lesional skin, as recommended by the British Association of Dermatologists 3
For moderate-to-severe disease, systemic corticosteroids with or without very potent topical steroids are recommended, according to the British Association of Dermatologists 3

Avoid using high-potency corticosteroids on the face, intertriginous areas, and genitals due to increased risk of skin atrophy, as advised by the American Academy of Dermatology 2
Use lower potency corticosteroids on the face (e.g., hydrocortisone) to avoid skin atrophy, as recommended by the National Comprehensive Cancer Network 4
Medium-potency corticosteroids have a lower risk of skin atrophy compared to high-potency options, making them suitable for longer courses of treatment, according to the American College of Dermatology 1

In children, lower potency corticosteroids should be used when possible, with monitoring for growth during long-term use, as recommended by the American Academy of Pediatrics and the American College of Dermatology 1
For hand-foot skin reactions from anticancer agents, topical high-potency steroids applied twice daily are recommended, according to the European Society for Medical Oncology 5
For grade I acute graft-versus-host disease affecting only the skin, medium to high-potency topical steroids are recommended, as suggested by the National Comprehensive Cancer Network 4

For limited, discrete papules and plaques in cutaneous sarcoidosis, high-potency topical agents like clobetasol or halobetasol propionate may be used, and intralesional injections of triamcinolone acetonide may be more effective than topical preparations for localized lesions, as recommended by the European Respiratory Society 6, 7
For widespread lesions in cutaneous sarcoidosis, topical/intralesional glucocorticoids are impractical, and systemic therapy should be considered, according to the European Respiratory Society 6, 7

After prolonged use of potent topical glucocorticoid agents, gradual tapering is recommended to prevent rebound, as suggested by the European Respiratory Journal 8